We advised Precigen on the SEC-registered offering

Davis Polk advised Precigen, Inc., as issuer, in connection with the SEC-registered offering of an aggregate of 39,878,939 shares of its common stock, no par value per share, having an aggregate offering price of approximately $34 million before underwriting discounts and estimated expenses of the offering. The common stock of Precigen, Inc. is listed on the Nasdaq Global Select Market under the symbol “PGEN.”

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. The company’s technologies are designed to enable it to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Arisa Akashi Sin, Jenny Li and Saloni Pant. Partner David R. Bauer and associate Brette L. Trost provided intellectual property advice. Partner Michael Mollerus and associates Michael Mirabella and Kelsey Nelson provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post